Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, Its Lead Drug Candidate For Treating ADHD

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD).

CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to address major limitations of current ADHD therapies. Cingulate submitted its NDA to the FDA for CTx-1301 on July 31, 2025.

Under the new agreement, Bend Bio Sciences will serve as the exclusive commercial manufacturer of CTx-1301 in the United States through 2028, if approved by the FDA, and Cingulate has committed to purchasing 100% of its overall U.S. commercial supply of CTx-1301 from Bend, following and subject to any FDA approval. This strategic arrangement provides manufacturing security and operational efficiency as Cingulate prepares for potential market entry.